Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Immunohistochemical evaluation of p63 and cyclin D1 in oral squamous cell carcinoma and leukoplakia

´ëÇѱ¸°­¾Ç¾È¸é¿Ü°úÇÐȸÁö 2017³â 43±Ç 5È£ p.324 ~ 330
Patel Sunit B., Manjunatha Bhari S., Shah Vandana, Soni Nishit, Sutariya Rakesh,
¼Ò¼Ó »ó¼¼Á¤º¸
 ( Patel Sunit B. ) - Ahmedabad Dental College Department of Oral Pathology
 ( Manjunatha Bhari S. ) - Taif University Faculty of Dentistry Department of Oral Biology, Basic Dental Sciences
 ( Shah Vandana ) - K.M.Shah Dental College Department of Oral Pathology
 ( Soni Nishit ) - Karnavati School of Dentistry Department of Oral Pathology
 ( Sutariya Rakesh ) - Vaidik Dental College Department of Oral Pathology

Abstract


Objectives: There are only a limited number of studies on cyclin D1 and p63 expression in oral squamous cell carcinoma (OSCC) and leukoplakia. This study compared cyclin D1 and p63 expression in leukoplakia and OSCC to investigate the possible correlation of both markers with grade of dysplasia and histological grade of OSCC.

Materials and Methods: The study included a total of 60 cases, of which 30 were diagnosed with OSCC and 30 with leukoplakia, that were evaluated immunohistochemically for p63 and cyclin D1 expression. Protein expression was correlated based on grades of dysplasia and OSCC.

Results: Out of 30 cases of OSCC, 23 cases (76.7%) were cyclin D1 positive and 30 cases (100%) were p63 positive. Out of 30 cases of leukoplakia, 21 cases (70.0%) were cyclin D1 positive and 30 (100%) were p63 positive (P¡´0.05).

Conclusion: The overall expression of cyclin D1 and p63 correlated with tumor differentiation, and increases were correlated with poor histological grades, from well-differentiated to poorly-differentiated SCC. Increased cyclin D1 and p63 expression was associated with the severity of leukoplakia. Based on these results cyclin D1 and p63 products can be a useful tool for improved leukoplakia prognosis.

Å°¿öµå

Cyclin D1; Immunohistochemistry; Leukoplakia; Oral squamous cell carcinoma; p63

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed